Navigation Links
Generics Analysis: Key Patent Case Reviews
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generics Analysis: Key Patent Case Reviews

http://www.reportlinker.com/p0968573/Generics-Analysis-Key-Patent-Case-Reviews.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.Detailed analysis of the likely date of generic entry for Cymbalta and RevlimidAnalysis of both products' position in their companies total prescription pharma portfolioCelgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016–27.In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.Gain clarity on when Cymbalta and Revlimid are likely to face generic competitionAssess the threat to Eli Lilly and Celgene of these products' genericization

 

GENERIC ENTRY TIMING REVIEWS•Key findings

•Cymbalta (duloxetine; Eli Lilly) - EU launch of generic Cymbalta from August 2014

•Revlimid (lenalidomide; Celgene) - Natco sued for infringement of 14 patents

 

APPENDIX•References

•Exchange rates

 

TABLES

•Table: Cymbalta: patent protection and exclusivity in Europe

•Table: Revlimid: patent protection and exclusivity in the US

•Table: Exchange rates, 2012

 

FIGURES

•Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002–17

•Figure: Revlimid and total Celgene sales, 2002–17

•Figure: US patent and exclusivity timeline relating to Revlimid

•Figure: Chemical structure of lenalidomide

 

Companies Mentioned

Devoteam SA, Hutchison 3G UK Limited

 

To order this report:

Drug_and_Medication Industry: Generics Analysis: Key Patent Case Reviews

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
3. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
4. Branded Generics in South East Asia: Current and Future Opportunities
5. Essential Medical Dismisses Patent Case against Masimo and Cercacor
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Broad Patent Protection Granted for iBio Immunomodulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... WHIPPANY, N.J. , Sept. 1, 2017  Bayer will ... at the European Society for Medical Oncology (ESMO) 2017 Congress, ... studies presented will include new preclinical and clinical data on ... from two earlier pipeline projects. ... of the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... HAMPTON, Va. , Aug. 29, 2017 ivWatch, LLC, ... of peripheral IV infiltrations, announced it has been awarded an Innovative ... improvement company in the country. ... A continuous monitoring device to aid in the early detection of ... The ...
(Date:8/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the Morgan ... New York . John Greisch , ... at 11:05 a.m. Eastern Time. The live ... recorded replay will be available one hour after the conclusion ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/22/2017)... , ... September 22, 2017 , ... ... you brush more effectively even on the go. Their electric toothbrushes aggressively attack ... gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... Lyme and other tick-borne diseases through research, education and awareness, today announced the ... A noted immunologist and microbiologist, Dr. Sellati has more than 20 years of ...
(Date:9/21/2017)... ... 21, 2017 , ... The American Addiction Treatment Association (AATA) ... in the addiction treatment industry entitled: Special Investigations Unit (SIU) – What ... state and federal governments are increasingly scrutinizing the addiction treatment industry for fraudulent ...
(Date:9/21/2017)... ... , ... In addition to sticking with the new years ... and use natural alternatives for all house cleaning products, disinfectants, respiratory relief, and ... the new line of essential oils, are all 100% organic and natural. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... A new ... recovery at a time when Virginia faces an opioid epidemic. , ... staggering increase of 38 percent from 2015, underscoring the need for additional addiction ...
Breaking Medicine News(10 mins):